Drugs / XY03-EA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05515393 | Sep 2022 → Dec 2023 | ischemic stroke | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06755944 | Dec 2024 → Jun 2025 overdue | ischemic stroke | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XY03-EA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06755944 ↗ |
| Route | Oral | “The 600-mg group took four tablets of XY03-EA once, three times a day.” NCT05515393 ↗ |